Tag Archives: carbapenem

CRE Surveillance Data from France

Posted on by — No Comments ↓

Despite all the concern about the emergence of CRE pathogens worldwide, it is quite difficult to obtain hard quantitative, prospectively collected incidence figures. A recent article by Robert [1] and colleagues provides useful data from France.  Using a practical definition of carbapenem-non-susceptibility (ertapenem > 0.5, imipenem, meropenem > 2, doripenem > 1), Continue reading CRE Surveillance Data from France→

What is the “Niche” for Ceftolozane / Tazobactam?

Posted on by — 2 Comments ↓

There are currently a total of 6 beta-lactam + beta-lactamase inhibitor combinations in clinical trials. It will be a steep learning curve for the pharma reps (and physicians) to understand the resistance classifications, the confusing ESBL definitions, the CRE nomenclature, and how this all matters in clinical practice, on the Continue reading What is the “Niche” for Ceftolozane / Tazobactam?→

The Breakpoint Dilemma

Posted on by — 1 Comment ↓

As antibiotic resistance increases over the years, originally established susceptibility breakpoints (S-I-R) are becoming less relevant.   This ‘creep’ towards higher MICs over time is a unique but well-known feature of antimicrobials ultimately making these drugs obsolete. In the past, FDA and CLSI did not bother to update breakpoints in Continue reading The Breakpoint Dilemma→